4 6 7 diethoxy 2 3 bis hydroxymethyl naphthalen 1 yl 1 2 methoxyethyl pyridin 2 1h one 2 carbomethoxy 4 cyano 4 3 cyclopropylmethoxy 4 difluroromethoxyphenyl cyclohexan1 one cis 4 cyano 4 3 cyclopropylmethoxy 4 difluoromethoxyphenyl cyclohexan 1 ol ono 6126 eur respir j 2003 22 suppl 45 abst 2557 and the compounds claimed in the pct patent applications number wo03 097613 and pct ep03 14722 and in the spanish patent application number p200302613 pde4 antagonists that can be combined with aclidinium in the present invention include tomelukast ibudilast pobilukast pranlukast hydrate zafirlukast ritolukast verlukast sulukast cinalukast iralukast sodium montelukast sodium 4 4 3 4 acetyl 3 hydroxy 2 propylphenoxy propylsulfonyl phenyl 4 oxobutyric acid 5 3 4 acetyl 3 hydroxy 2 propylphenoxy propyl thio 1 3 4 thiadiazol 2 yl thio acetic acid 9 4 acetyl 3 hydroxy 2 n propylphenoxy methyl 3 1h tetrazol 5 yl 4h pyrido 1 2 a pyrimidin 4 one 5 3 2 7 chloroquinolin 2 yl vinyl phenyl 8 n n dimethylcarbamoyl 4 6 dithiaoctanoic acid sodium salt 3 1 3 2 7 chloroquinolin 2 yl vinyl phenyl 1 3 dimethylamino 3 oxopropylsulfanyl methy sulfanyl propionic acid sodium salt 6 2 cyclohexylethyl 1 3 4 thiadiazolo 3 2 a 1 2 3 triazolo 4 5 d pyrimidin 9 1h one 4 6 acetyl 3 3 4 acetyl 3 hydroxy 2 propylphenylthio propoxy 2 propylphenoxy butyric acid r 3 methoxy 4 1 methyl 5 n 2 methyl 4 4 4 trifluorobutyl carbamoyl indol 3 ylmethyl n.